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Eﬀ ect of a serogroup A meningococcal conjugate vaccine 
(PsA–TT) on serogroup A meningococcal meningitis and 
carriage in Chad: a community study
D M Daugla , J P Gami, K Gamougam, N Naibei, L Mbainadji, M Narbé, J Toralta, B Kodbesse, C Ngadoua, M E Coldiron, F Fermon, A-L Page, 
M H Djingarey, S Hugonnet, O B Harrison, L S Rebbetts, Y Tekletsion, E R Watkins, D Hill, D A Caugant, D Chandramohan, M Hassan-King, 
O Manigart, M Nascimento, A Woukeu, C Trotter, J M Stuart, M C J Maiden, B M Greenwood
Summary
Background A serogroup A meningococcal poly saccharide–tetanus toxoid conjugate vaccine (PsA–TT, MenAfriVac) 
was licensed in India in 2009, and pre-qualiﬁ ed by WHO in 2010, on the basis of its safety and immunogenicity. This 
vaccine is now being deployed across the African meningitis belt. We studied the eﬀ ect of PsA–TT on meningococcal 
meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic.
Methods We obtained data for the incidence of meningitis before and after vaccination from national records between 
January, 2009, and June, 2012. In 2012, surveillance was enhanced in regions where vaccination with PsA–TT had 
been undertaken in 2011, and in one district where a reactive vaccination campaign in response to an outbreak of 
meningitis was undertaken. Meningococcal carriage was studied in an age-stratiﬁ ed sample of residents aged 
1–29 years of a rural area roughly 13–15 and 2–4 months before and 4–6 months after vaccination. Meningococci 
obtained from cerebrospinal ﬂ uid or oropharyngeal swabs were characterised by conventional microbiological and 
molecular methods.
Findings Roughly 1·8 million individuals aged 1–29 years received one dose of PsA–TT during a vaccination campaign 
in three regions of Chad in and around the capital N’Djamena during 10 days in December, 2011. The incidence of 
meningitis during the 2012 meningitis season in these three regions was 2·48 per 100 000 (57 cases in the 2·3 million 
population), whereas in regions without mass vaccination, incidence was 43·8 per 100 000 (3809 cases per 8·7 million 
population), a 94% diﬀ erence in crude incidence (p<0·0001), and an incidence rate ratio of 0·096 (95% CI 
0·046–0·198). Despite enhanced surveillance, no case of serogroup A meningococcal meningitis was reported in the 
three vaccinated regions. 32 serogroup A carriers were identiﬁ ed in 4278 age-stratiﬁ ed individuals (0·75%) living in a 
rural area near the capital 2–4 months before vaccination, whereas only one serogroup A meningococcus was isolated 
in 5001 people living in the same community 4–6 months after vaccination (adjusted odds ratio 0·019, 95% CI 
0·002–0·138; p<0·0001).
Interpretation PSA–TT was highly eﬀ ective at prevention of serogroup A invasive meningococcal disease and carriage 
in Chad. How long this protection will persist needs to be established.
Funding The Bill & Melinda Gates Foundation, the Wellcome Trust, and Médecins Sans Frontières.
Introduction
For more than 100 years, the Sahelian and sub-Sahelian 
regions of Africa have had periodic, large, and un-
predictable epidemics of meningococcal meningitis.1 
The ﬁ rst outbreaks in Chad were reported in 1916 and 
1918,2 and major epidemics arose in 1924 and 1935–39, 
with a mortality rate of more than 75% in both epidemics.3 
Another major cycle began in 1943, when more than 
2000 cases were reported, and further epidemics arose in 
the 1950s and 1960s. In 1968, an outbreak including 
272 cases was reported in the capital N’Djamena 
(formerly Fort Lamy), but mortality was only 10% after 
introduction of treatment with sulphonamides, peni-
cillin, or chloramphenicol.4 A large epidemic in the 
Logone Occidental region in 1988, and an outbreak in the 
Goundi district in 2001, showed the characteristic 
seasonality of epidemic meningitis in Africa.5,6 A new, 
nationwide epidemic in 2009–12 included 1000 cases.7 
Serogroup A meningococci were present in all early 
outbreaks in which the epidemic strain was charac-
terised.8,9 However, serogroup W meningococci were 
isolated from 2005 onwards, and both serogroup A and 
serogroup W infections were detected during the 2009 
epidemic, with the preponderant serogroup varying 
between areas.10
Chad was one of the ﬁ rst countries in Africa to attempt 
to prevent meningococcal disease by vaccination. In 1936, 
a serogroup A whole cell vaccine was produced at Sarh 
(formerly Fort Archambault) and widely distributed 
throughout Chad with apparent success, although no 
clinical trial was done.11 Polysaccharide vaccines were ﬁ rst 
used extensively in the 1988 epidemic. An initial 
campaign in which vaccination was restricted to 
schoolchildren and the military had little or no eﬀ ect on 
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the course of the epidemic. A second universal vaccination 
campaign might have been more eﬀ ective, but vaccination 
was introduced near the end of the season when the 
epidemic was expected to decrease.12 Sarh was included in 
this campaign, but a major outbreak happened in the 
town 2 years later,13 and epidemics have continued in 
Chad despite widespread use of polysaccharide vaccines 
in reactive vaccination campaigns.
Polysaccharide–protein conjugate vaccines are more 
likely to prevent epidemics than are polysaccharide 
vaccines because conjugate vaccines are immunogenic 
in young children, induce immunological memory, and 
prevent pharyngeal carriage.14 Because most of the 
meningococcal epidemics in Africa have been caused by 
serogroup A meningococci, the Meningitis Vaccine 
Project (MVP), a public–private partnership between 
WHO and PATH, was established in 2001, with support 
from the Bill & Melinda Gates Foundation, to develop an 
aﬀ ordable, monovalent serogroup A conjugate vaccine. 
As a result of an innovative and successful north–south 
development programme, a serogroup A polysaccharide–
tetanus toxoid conjugate vaccine (PsA–TT, MenAfriVac) 
was developed at the Serum Institute of India (Pune, 
India). This vaccine was licensed in India in 2009, and 
pre-qualiﬁ ed by WHO in 2010, on the basis of the safety 
and high immunogenicity of the vaccine;15 no phase 3 
eﬃ  cacy trial was undertaken. Thus, assessment of the 
eﬃ  cacy of PsA–TT after licensure is essential. Roll-out of 
PsA–TT, supported by the MVP, WHO, UNICEF, and 
GAVI Alliance, started in December 2010, when nearly 
all 1–29 year-olds in Burkina Faso were vaccinated during 
6 weeks.16 In the year after this campaign, the incidence 
of overall cases of meningitis in Burkina Faso fell to the 
lowest rate recorded since 1995, no local outbreaks were 
reported, and no case of serogroup A disease was 
detected.17 At the same time, a marked drop in the 
prevalence of serogroup A meningococcal carriage was 
noted in three districts in which carriage surveys were 
done.18 These results strongly suggested a major eﬀ ect of 
PsA–TT on serogroup A meningococcal disease and 
carriage, but they cannot be regarded as deﬁ nitive 
because the vaccine was introduced at a time of very low 
and decreasing transmission of the serogroup A 
meningococcus in the central part of the African 
meningitis belt. In 2011, Chad and northern Cameroon 
were the only parts of the African meningitis belt where 
serogroup A cases were detected in substantial numbers.19
The African Meningococcal Carriage Consortium 
(MenAfriCar) was established to study the epidemiology 
of meningococcal carriage in countries of the African 
meningitis belt before and after the introduction of PsA–
TT.20 MenAfriCar started work in Chad in 2009 and was, 
therefore, able to measure the eﬀ ect of PsA–TT on 
meningitis and meningococcal carriage in this country 
after the ﬁ rst phase of mass vaccination in 2011.
Methods
Study area
Chad is one of the largest countries in Africa with a 
surface area greater than 1 million km². The north of the 
country is desert, the centre is arid Sahel, and the south a 
more fertile Sudan Savanna zone. The central and 
southern parts of the country have a typical Sahelian 
climate with a short rainy season, maximum in the 
south, and a long dry season during which epidemics of 
meningitis can happen. The population, roughly 
11 million, is concentrated in the southern part of the 
country. Health care is provided through about 800 health 
centres, 60 district hospitals, ten regional hospitals, and 
two tertiary hospitals in N’Djamena.
Surveillance for meningitis
Clinically diagnosed cases and deaths due to meningitis 
are recorded at all health centres and district hospitals in 
Chad and these aggregated data are transmitted every 
week to the district medical oﬃ  cer. Data from each district 
are submitted to the integrated epidemiological service of 
the Ministry for Public Health, which passes this 
information on to the WHO Inter-Country Support Team 
in Ouagadougou, Burkina Faso (ﬁ gure 1). Cerebrospinal 
ﬂ uid (CSF) samples are collected, transferred to the 
central hospital in N’Djamena, and tested by routine 
microbiology or by latex test; the latex test is also being 
used in the ﬁ eld. The completeness of case ascertainment 
is unknown. From March 1, 2012, to June 30, 2012, 
surveillance was enhanced, with support from the 
MenAfriCar consortium, in the three regions (N’Djamena, 
Chari-Baguirmi, and Mayo-Kebbi Est) in which individuals 
aged 1–29 years (target population 1·8 million) had been 
vaccinated with PsA–TT during 10 days in December, 
2011, shortly before the 2012 epidemic season. A nurse 
and a laboratory technician were identiﬁ ed at each hospital 
and given responsibility to complete a case report form on 
any suspected case of meningitis and to ensure that CSF 
samples were transported to the national reference 
laboratory in a plain tube and in trans-isolate medium. 
For more on the MVP see http://
www.meningvax.org/
Figure 1: Reported cases of meningitis in Chad from 1930–2012
Arrows show the introduction of new control measures.
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Additionally, case surveillance was established during an 
outbreak from March 4, to May 5, 2012, in one district 
(Moissala) that had not received PsA–TT and where 
reactive vaccination was undertaken.
Carriage studies
Between September and November, 2010, we did a 
carriage survey in 998 age-stratiﬁ ed residents of the rural 
area of Mandelia, roughly 65 km south of N’Djamena. 
Between August and October, 2011, we did a pre-
vaccination survey in 4278 age-stratiﬁ ed individuals; 
between April and June, 2012, a survey was done after 
vaccination in 5001 individuals in the same community, 
sampled so that four age groups (0–4 years, 5–14 years, 
15–29 years, and >30 years) were adequately represented. 
A higher proportion of school age children and young 
adults were included in the post-vaccination survey to 
increase the likelihood of detection of serogroup A 
carriers. Details of the sampling methods and swabbing 
techniques used are described elsewhere.20
Laboratory methods
CSF samples were gram stained, tested for microbial 
antigens (Pastorex test, Bio-Rad Laboratories, Marnes-la-
Coquette, France), and cultured on chocolate agar or 
Thayer-Martin agar (Oxoid SR0091E, Oxoid Ltd, 
Basingstoke, UK]) with antibiotic supplements (3 mg/L 
vancomycin, 7·5 mg/L colistin, 1250 U/L nystatin, and 
5 mg/L trimethoprim) with incubation in 5–10% carbon 
dioxide. Meningococci identiﬁ ed by morphology and 
biochemical tests (API NH or VITEK2 Compact, 
Biomérieux, Marcy l’Etoile, France) were serogrouped by 
agglutination, and the antimicrobial sensitivity of 
meningococci was established. PorA and genogrouping 
PCR were done on specimens from the area where 
reinforced surveillance had been introduced in 2012. 
Strains isolated from cases of meningitis were stored in 
brain infusion broth with glycerol at –80°C and sent to 
the Inter-Country Support Team, Ouagadougou, and to 
the WHO Collaborating Centre for Reference and 
Research on Meningococci in Oslo, Norway. CSF samples 
collected in trans-isolate medium from outbreak areas by 
a team from Médecins Sans Frontières (MSF) were 
analysed by genogrouping and PorA PCR in Oslo.
The laboratory methods used to detect meningococcal 
carriage are described in detail elsewhere.20 In brief, 
swabs were plated directly onto a modiﬁ ed Thayer-Martin 
plate containing antibiotics and transferred to the 
laboratory within 6 h of collection. Colonies with a 
morphology characteristic of Neisseria species were 
subcultured onto two blood agar plates. Isolates that 
were γ-glutamyl transpeptidase (GGT) positive, 
o-nitrophenyl-β-d-galactopyranoside (ONPG) negative, 
and tributyrin negative were characterised as presumptive 
N meningitidis and serogrouped by slide agglutination. 
Heat-killed cell suspensions were prepared from all 
isolates characterised as oxidase-positive, Gram-negative 
diplococci and sent to the Department of Zoology, 
University of Oxford, Oxford, UK, for molecular 
conﬁ rmation of speciation, genogroup, and porA 
genosubtype. Neisseria species were conﬁ rmed by 
sequencing a 413 bp fragment of the rplF ribosomal 
subunit gene,21 and samples not conﬁ rmed as Neisseria 
were speciated by sequencing the 16S rRNA gene.22 The 
capsule region was characterised by sequencing to 
identify the capsule null (cnl) region23 and a real-time 
PCR assay was used to detect genes encoding serogroup 
A, W, and X capsular poly saccharides.24 Sequencing of 
the porA gene conﬁ rmed likely membership of the 
sequence type 5 (ST-5) clonal complex (formerly known 
as subgroup 3),25 which has caused serogroup A 
epidemics in the meningitis belt since the Hajj epidemics 
of the late 1980s.26
Statistical analysis
We used data from the 2009 census as the denominator 
to calculate incidence rates. To assess the eﬀ ect of PsA–
TT on the incidence of meningitis, we analysed weekly 
incidence data collected during the 26 weeks of active 
surveillance each year from Jan 1, 2009, to June 30, 2012, 
from two areas, one of which was vaccinated in 2012 
(area one), and the other remained unvaccinated (area 
two). We measured the eﬀ ect of vaccination in two ways 
with a negative binomial regression model. First, we 
assessed the crude diﬀ erence in total incidence in 2012 
between vaccinated and unvaccinated areas. Then, to 
estimate the eﬀ ect of vaccination above the diﬀ erence 
between the areas in 2009–11, we incorporated an 
interaction term for area one in 2012.
To assess the eﬀ ect of PsA–TT on carriage of serogroup 
A meningococci, we compared the prevalence of carriage 
before and after vaccination in Mandelia (rural area) with 
a logistic regression model adjusted for age. This 
adjustment was necessary because the sampling strategy 
had been modiﬁ ed between the 2011 and 2012 surveys, 
with the 2012 survey sampling fewer younger children 
who were shown in 2011 to rarely carry meningococci. All 
analyses were done with Stata (version 12.0). We 
estimated vaccine coverage in the targeted group aged 
1–29 years as the total number vaccinated divided by the 
population size in 2009. The study is registered with 
ClinicalTrials.gov, number NCT01119482.
Role of the funding sources
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
The present epidemic of meningitis in Chad began in 
2009 with an upsurge in cases of both serogroup A and 
serogroup W meningococcal meningitis. 3058 cases were 
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reported in 2010, 5960 in 2011, and 3795 in 2012 (ﬁ gure 2). 
During 2011 and 2012, most meningococcal isolates 
obtained were serogroup A (data not shown). In the three 
regions in which vaccination was undertaken in 
December, 2011, estimated vaccine coverage was 102%. 
These regions were chosen for logistical reasons. 
Nationwide vaccination of the 1–29-year-old population 
was achieved in three further phases between June and 
December, 2012, with estimated vaccine coverage of 95%, 
95%, and 81%, respectively. Coverage in the last phase of 
the vaccination campaign fell after reports of adverse 
events after vaccination, concerns that were subsequently 
shown to be unfounded.27
Reactive vaccination campaigns with serogroups A 
and C or serogroups A,C, and W plain polysaccharide 
vaccines were implemented in response to outbreaks in 
nine districts in 2009 (A+C), in eight districts in 2010 
(A+C [three]; A+C+W [ﬁ ve]), and in 12 districts and the 
refugee camp of Tréguine (district of Adré) in 2011 
(A+C). Between February and May, 2012, reactive 
vaccination campaigns with the PsA–TT conjugate 
vaccine were done in nine districts that had passed the 
epidemic threshold and in three other districts next to 
epidemic districts. Vaccine coverage with PsA–TT in 
the target population (1·5 million) during the 2012 
reactive vaccination campaigns was estimated to be 
94%. In ﬁ ve of the 12 districts that received PsA–TT in 
2011, reactive vaccination with polysaccharide sero-
groups A and C vaccine had been done in 2009. Reactive 
vaccination campaigns with polysaccharide vaccines 
were not undertaken in any of these 12 districts in 2010, 
2011, or 2012.
The incidence of reported cases of meningitis during 
the ﬁ rst 26 weeks of 2012 in the three regions where 
vaccination with PsA–TT of individuals aged 1–29 years 
had been undertaken the previous year was 2·48 per 
100 000 (57 cases per 2·3 million population). By contrast, 
the incidence in areas where PsA–TT vaccination had 
not been undertaken as part of the mass campaign, 
including the areas where reactive vaccination was 
undertaken in response to an outbreak, was 43·8 per 
100 000 (3809 cases per 8·7 million population), a 94% 
diﬀ erence in total incidence in 2012 (p<0·0001). 
17 districts reached the alert or epidemic threshold in 
2012, none of which were in the three vaccinated regions 
(ﬁ gure 2). The diﬀ erence in incidence between vaccinated 
and unvaccinated regions recorded in 2012 showed a 
marked change from the pattern recorded in the previous 
3 years (ﬁ gure 3). Results from a negative binomial 
regression model suggest a 90·4% (p<0·0001) overall 
reduction in the risk of meningitis after mass vaccination, 
with an estimated incidence rate ratio of 0·096 (95% CI 
0·046–0·198).
In 2012, laboratory conﬁ rmation of a diagnosis of 
meningococcal meningitis was made in 65 of 366 CSF 
samples (18%) submitted to the national reference 
laboratory in N’Djamena. A diagnosis of serogroup A 
meningococcal meningitis was made by culture or latex 
test in 59 of 329 samples from people in regions where 
vaccination had not been done previously with PsA–TT. 
Serogroup A meningococcus was not isolated from any 
of the 37 samples from the three vaccinated regions with 
enhanced surveillance (table 1), even though only 
Figure 2: Areas of Chad vaccinated with PsA–TT in 2011, or in epidemic or 
alert situation during Jan–June 2012
Green shading shows the districts where mass vaccination of people aged 
1–29 years was undertaken at the end of 2011, before the 2012 meningitis 
season. Red shading shows the districts where the alert or epidemic threshold 
was reached during the course of the 2012 meningitis season. PsA–TT=serogroup 
A meningococcal polysaccharide–tetanus toxoid conjugate vaccine.
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Figure 3: Incidence of reported cases of meningitis in Chad, 2009–12
Vaccination with PsA–TT was undertaken in patients aged 1–29 years at the end of 2011 (arrow). 
PsA–TT=serogroup A meningococcal polysaccharide–tetanus toxoid conjugate vaccine.
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individuals aged 1–29 years had been vaccinated. Ten 
serogroup A isolates obtained from cases of meningitis 
studied at the National Institute for Public Health, Oslo, 
Norway, were all characterised as belonging to ST-7 of the 
ST-5 clonal complex, subtype P1·20,9.
The incidence of meningitis reached the epidemic 
threshold in weeks 6–22 in 12 districts, initiating reactive 
vaccination campaigns undertaken by the Ministry of 
Health, WHO, MSF, and other agencies. The eﬀ ect of 
reactive vaccination was studied in detail in one district 
(Moissala, attack rate 148 per 100 000 population, case 
fatality rate 3·4%) where CSF samples were obtained 
from 176 of 334 (53%) reported cases. Before vaccination 
with PsA–TT, 48 serogroup A infections were detected by 
latex agglutination and 35 by culture or PCR; the data for 
serogroup W were 18 and 17, respectively. After the 
vaccination campaign, only one further case of serogroup 
A meningitis was detected in a 9-year-old girl who had 
been vaccinated 5 days previously (appendix).
The prevalence of meningococcal carriage in the rural 
area of Mandelia varied with age, and was most frequent 
in individuals aged 1–29 years. The overall prevalence of 
meningococcal carriage was low in two surveys 
undertaken before, and one survey undertaken after 
vaccination of individuals aged 1–29 years with PsA–TT 
(table 2). Serogroup A carriers were deﬁ ned according to 
the characteristics of their pharyngeal isolate—namely, 
whether the isolate provided DNA corres ponding to 
either serogroup A capsule region, rplF allele 1 (rplF-1) 
and a porA gene encoding the subtype P1·20,9 (criterion 
one); or to a serogroup A capsular gene alone (criterion 
two). The ﬁ rst deﬁ nition was regarded as conﬁ rmation 
that the individual was carrying an epidemic strain—ie, 
a serogroup A, ST-5 clonal complex meningococcus. 
Most of the individuals with serogroup A capsular DNA 
were probably also carry ing such a strain, perhaps at 
a low density. 2–4 months before vaccination, 32 of 
4278 individuals (0·75%) met criterion one and an 
additional 12 met criterion two. 4–6 months after the 
vaccination campaign, only one of 5001 individuals 
tested (0·02%) met criterion one, a 98% diﬀ erence in 
prevalence (adjusted odds ratio 0·019, 95% CI 
0·002–0·138), and no additional individual met criterion 
two. The one serogroup A carrier detected after vaccin-
ation was a 15-year-old boy who, according to his 
vaccination card, had been vaccinated with PsA–TT 
4 months before detection. The number of individuals 
carrying serogroup A fell in the unvaccinated age 
groups from seven of 1374 before vaccination to zero of 
336 individuals after vaccination (p=0·19).
Discussion
This study has established the ability of a new serogroup 
A meningococcal conjugate vaccine (PsA–TT) to prevent 
epidemic meningitis in Chad, a country within the African 
meningitis belt where epidemics are frequent and severe. 
The vaccine halted a continuing epidemic in districts 
around the capital N’Djamena while the epidemic 
continued in other parts of the country.  Vaccination was 
associated with a marked drop in pharyngeal carriage of 
the serogroup A epidemic strain, and this probably 
contributed to the substantial eﬀ ect of the vaccine.
Measurement of the eﬀ ectiveness of a vaccine after its 
introduction is especially important when licensure has 
been based solely on safety and immunogenicity, as has 
Number of 
CSF samples
Diagnosis*
Meningococci Pneumococci Other
A W X Other
Non-vaccinated regions†
1–29 years 305 57 3 0 0 2 0
<1 or ≥30 years 24 2 1 0 0 2 0
Total 329 59 4 0 0 4 0
Vaccinated regions
1–29 years 34 0 0 2 0 0 0
<1 or ≥30 years‡ 3 0 0 0 0 0 0
Total 37 0 0 2 0 0 0
CSF=cerebrospinal ﬂ uid. *Diagnosis based on culture or latex test. †Includes 
regions where reactive vaccination in response to an outbreak was undertaken. 
‡Not in the target group for vaccination.  
Table 1: Diagnosis of serogroup A meningococcal meningitis in individuals 
from non-vaccinated and vaccinated regions in Chad
Number tested Meningococci isolated
All A, P1·20,9* W X Other†
Survey one (September–November, 2010, 13–15 months before vaccination)
<1 year 74 0 0 0 0 0
1–29 years 670 6 6 0 0 0
≥30 years 254 0 0 0 0 0
Total 998 6 6 0 0 0
Carriage prevalence ·· 0·6% 0·6% 0% 0% 0%
Survey two (August–October, 2011, 2–4 months before vaccination)
<1 year 260 1 1 0 0 0
1–29 years 2904 45 25‡ 3 6 11
≥30 years 1114 10 6 0 0 4
Total 4278 56 32 3 6 15
Carriage prevalence ·· 1·3% 0·7% 0·07% 0·1% 0·4%
Survey three (April–June, 2012, 4–6 months after vaccination)
<1 year 68 0 0 0 0 0
1–29 years 4665 39 1 1 5 32
≥30 years 268 2 0 0 0 2
Total 5001 41 1 1 5 34
Carriage prevalence ·· 0·8% 0·02% 0·02% 0·1% 0·7%
PsA–TT=serogroup A meningococcal polysaccharide–tetanus toxoid conjugate vaccine. *Specimens in which the 
meningococcal serogroup A capsular region, rplF allele 1 (rplF-1), and a porA gene subtypes P1·20,9 were detected. 
†Other serogroups include specimens that were conﬁ rmed as Neisseria meningitidis, but not characterised as serogroup 
A subtype P1·20,9 or serogroup X or W. Further inf ormation about these specimens are given in the appendix. ‡One of 
these specimens yielded both a serogroup A and a serogroup X meningococcus.  
Table 2: Meningococcal carriage in the Mandelia district of Chad before and after vaccination with PsA–TT
See Online for appendix
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been the case for PsA–TT and other conjugate vaccines. 
Studies done before and after vaccination can provide 
some evidence for an eﬀ ect,28 but can be aﬀ ected by 
temporal changes in disease incidence that are indepen-
dent of any intervention. This constraint applies 
especially to infections that tend to be epidemic such as 
meningococcal infection. The fact that only part of Chad 
was vaccinated at the end of 2011 provided a unique 
opportunity to measure the eﬀ ect of PsA–TT on 
serogroup A meningococcal disease by measurement of 
disease incidence in vaccinated and unvaccinated areas 
at the same time. 
At the end of 2011, shortly before the 2012 epidemic 
season, vaccination of individuals aged 1–29 years (target 
population 1·8 million) was undertaken in three regions 
of Chad. The estimated coverage of the mass campaign 
was 102%. This apparently anomalous ﬁ gure might be 
indicative of inaccuracies in the census data used as a 
denominator because the census was done 3 years before 
vaccination. Other possible explanations could be that 
individuals older than the targeted limit of 29 years were 
vaccinated, people travelled to the region to be 
immunised, or some individuals were vaccinated twice.
During the 2012 meningitis season, the incidence of 
meningitis fell substantially in areas of Chad where 
individuals aged 1–29 years had been vaccinated with 
PsA–TT a few months previously while the epidemic 
continued in neighbouring non-vaccinated areas. The 
disparity between vaccinated and non-vaccinated groups 
was probably even greater than we have reported here for 
two reasons. First, surveillance for cases of meningitis 
was enhanced in the vaccinated areas but, for ﬁ nancial 
and logistical reasons, not in the rest of the country 
where reporting of cases was dependent upon a less 
rigorous routine surveillance system. Despite enhanced 
surveillance, no case of serogroup A meningitis was 
detected in a population of roughly 2 million residents in 
the vaccinated areas. Second, reactive vaccination was 
undertaken in the middle of the 2012 meningitis season 
in 12 districts that had passed the epidemic threshold. 
Had reactive vaccination not been undertaken in these 
districts, more cases would probably have been recorded, 
increasing the disparity in incidence between unvac-
cinated and vaccinated areas.
Because vaccinated and non-vaccinated districts were 
not randomised, the diﬀ erence in incidence of meningitis 
between vaccinated and non-vaccinated areas could have 
been caused by random ﬂ uctuations in disease incidence. 
However, we think that this situation is very unlikely for 
two main reasons. First, surveillance data suggest that 
the epidemic was progressing in a similar way in 
vaccinated and in unvaccinated areas before vaccination 
(ﬁ gure 3), and second, the geographical distribution of 
cases in the 2012 outbreak (ﬁ gure 1) suggests that the 
vaccinated areas where no cases were recorded are 
surrounded by areas where the epidemic or alert 
threshold was reached.
The drop in the number of cases of meningitis recorded 
in vaccinated areas was accompanied by a 98% decrease 
in the prevalence of serogroup A meningococcal carriage 
in all age groups in a rural area where the serogroup A 
meningococcal carriage rate had been about 1% before 
vaccination with PsA–TT. This decrease was equally large 
when the deﬁ nition of carriage was detection of the 
serogroup A epidemic strain or the likely presence of a 
serogroup A meningococcus. For logistical and ﬁ nancial 
reasons, carriage studies in non-vaccinated areas during 
the period in which post-vaccination carriage ﬁ ndings 
were made in the vaccinated population were not 
possible. However, the fact that the incidence of 
serogroup A disease remained high in these non-
vaccinated areas suggests that transmission of the 
serogroup A meningococcus was continuing in these 
districts and that carriers were present.
No cases of serogroup A meningitis were detected in 
residents of the vaccinated areas who were too young or 
too old to be vaccinated. Only eight cases of meningitis 
of any kind were reported in this population, although 
about 100 would have been expected in view of the 
overall attack rate in the unvaccinated population and 
the age distribution of cases detected in the unvaccin-
ated Moissala district. These ﬁ ndings, together with the 
Panel: Research in context
Systematic review
We searched PubMed with the search terms “Africa” AND (“Neisseria” OR 
“meningococci”) AND “vaccine” AND “conjugate” AND (“ev aluation” OR “impact” OR 
“eﬀ ectiveness” OR “uptake” OR “coverage”), to identify papers published between Jan 1, 
2010, and May 1, 2013, because 2010 was the ﬁ rst year that serogroup A meningococcal 
polysaccharide–tetanus toxoid conjugate vaccine (PsA–TT, MenAfriVac) was used after 
phase 1 and 2 clinical trials. Five of the 27 papers retrieved were relevant to understanding 
the eﬀ ect of population-based vaccination campaigns with PsA–TT. Three studies 
reported high vaccine uptake in Burkina Faso29 and Niger.30,31 Two papers from Burkina 
Faso reported the eﬀ ect of PsA–TT introduction on rates of meningitis18 and 
meningococcal carriage.19 In the study of meningitis rates, which analysed meningitis 
incidence rates from surveillance data, a mass vaccination campaigns in people aged 
1–29 years was estimated to reduce the risk of meningitis by 71% overall, whereas the risk 
of disease caused by laboratory-conﬁ rmed serogroup A Neisseria meningitidis fell by 
99·8%. However, the incidence of serogroup A meningitis was low at the time of vaccine 
introduction in this country. The carriage surveys in Burkina Faso did not identify any 
serogroup A carriers after vaccination, compared with a baseline prevalence of 0·39%.
Interpretation
Our study is the ﬁ rst to measure the eﬀ ect of PsA–TT on meningococcal disease and 
carriage in a country with an epidemic of serogroup A meningitis at the time of vaccine 
introduction. The incidence of meningitis fell substantially in vaccinated areas whereas 
the epidemic continued in unvaccinated parts of the country. PsA–TT seems to be highly 
eﬀ ective against both serogroup A meningococcal disease and carriage. Questions remain 
about the duration of protection provided by this vaccine and whether elimination of the 
serogroup A meningococcus will be followed by an upsurge in cases caused by 
meningococci belonging to other serogroups. To answer these questions will need 
continued surveillance for meningitis and further carriage studies in countries of the 
African meningitis belt.
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absence of any serogroup A meningococcal carriage in 
the unvaccinated population in the areas where mass 
vaccination had been undertaken, suggest that PsA–TT 
has an important, indirect eﬀ ect on serogroup A 
carriage and disease, in keeping with the results of 
studies in Burkina Faso (panel).17,18 The result of studies 
done before and after intervention in Burkina Faso 
suggested that PsA–TT had a major eﬀ ect on both the 
incidence of meningitis and of serogroup A carriage in 
that country,17,18 but the incidence of serogroup A disease 
in Burkina Faso was falling before the introduction of 
the vaccine and so the further decrease recorded in 2011 
could have been caused by naturally acquired immunity 
to the epidemic clone. Because national vaccination 
coverage was achieved within a short period in Burkina 
Faso, the comparison of data from vaccinated and non-
vaccinated areas was not possible. By contrast, in Chad, 
we were able to describe the incidence of meningitis in 
vaccinated and unvaccinated areas over the same period 
during an epidemic.
Data from studies done in Chad strongly suggest that 
PsA–TT has a major eﬀ ect on serogroup A meningococcal 
disease and carriage and support the continuing roll-out 
of this vaccine across the African meningitis belt. 
However, several more years of active surveillance are 
needed to establish the duration of protection provided 
by PsA–TT, whether the vaccine can prevent future 
epidemics, and whether reduction of serogroup A 
meningococcal carriage will lead to an increase in 
carriage with other meningococci.32 Replacement could 
be beneﬁ cial if the strain that replaces the serogroup A 
meningococcus is non-pathogenic, or it could be a major 
concern for future vaccination strategies if the re-
placement strain is able to cause epidemics.
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